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ABSTRACT
Introduction: Despite recommendations that
general practitioners (GPs) delay antibiotic
prescribing for respiratory tract infections
(RTIs), antibiotic prescriptions in primary care
in England increased by 4.1% from 2010 to
2013. C-reactive protein (CRP) point-of-care
tests (POCT), for example, the Aﬁnion
TM
Analyzer (Alere Ltd, Stockport, UK) device, are
widely used in several countries in the European
Union. Studies suggest that CRP POCT use,
either alone or in combination with
communication training, reduces antibiotic
prescribing and improves quality of life for
patients presenting with RTI symptoms. The
aim of this study is to evaluate the cost-
effectiveness of CRP POCT for RTIs in primary
care in England over 3 years for three different
strategies of care compared to standard practice.
Methods: An economic evaluation was carried
out to compare the costs and beneﬁts of three
different strategies of CRP testing (GP plus CRP;
practice nurse plus CRP; and GP plus CRP and
communication training) for patients with RTI
symptoms as deﬁned by National Institute for
Health and Care Excellence guideline CG69,
compared with current standard GP practice
without CRP testing. Analysis consisted of a
decision tree and Markov model to describe the
quality-adjusted life years (QALYs) and cost per
100 patients, together with the number of
antibiotic prescriptions and RTIs for each
group.
Results: Compared with current standard
practice, the GP plus CRP and practice nurse
plus CRP test strategies result in increased
QALYs and reduced costs, while the GP plus
CRP testing and communication training
strategy is associated with increased costs and
reduced QALYs. Additionally, all three CRP
arms led to fewer antibiotic prescriptions and
infections over 3 years.
Conclusion: The additional cost per patient of
the CRP test is outweighed by the associated
cost savings and QALY increment associated
with a reduction in infections in the long term.
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INTRODUCTION
In England, clinical guidance from the National
Institute for Health and Care Excellence (NICE)
on respiratory tract infection (RTI) recommends
that general practitioners (GPs) delay
prescribing of antibiotics and advise patients
that antibiotics may have no impact on
symptoms in suspected viral infections [1].
Despite this recommendation, antibiotic
prescribing increased by 4.1% between 2007
and 2011 in England [2]. As most of these
infections are likely to be viral and current
evidence suggests that antibiotic prescribing
confers no additional beneﬁt [3], it is likely
that most of the prescribing is unnecessary and
increases the risk of antibiotic-resistant
infections. The Department of Health has
developed a 5-year strategy running from 2013
to 2018 in England which aims to slow the
development and spread of antimicrobial
resistance, by prescribing antibiotics only to
patients who are likely to beneﬁt [4].
C-reactive protein (CRP) point-of-care tests
(POCT) are widely used in many European
Union (EU) countries for antibiotic
prescription decision-making, and a meta-
analysis found that they signiﬁcantly reduce
antibiotic prescribing compared to usual care
[5]. Other studies have provided evidence that
communication training for health-care
professionals can be an effective way to reduce
the prescription of antibiotics to patients with
RTIs [6, 7].
Cost-effectiveness analyses conducted
previously have shown that although CRP
tests cost more per patient in the short term
(€11.27 per patient in Oppong et al. [8]), this is
balanced by a reduction in antibiotic
prescriptions (€112.70 per prescription
avoided) and improved quality of life [8].
Evidence of the cost-effectiveness of CRP tests
for RTIs versus current practice is limited to
analyses alongside trials, none of which look at
costs and outcomes beyond 28 days or from the
National Health Service (NHS) England
perspective.
The aim of this study is to present the results
of a decision analytic model of the cost-
effectiveness of near-patient CRP tests for RTI
in NHS England over 3 years.
METHODS
Basic Characteristics of Analysis
The model compares the current standard in GP
practice, where patients presenting with RTI
symptoms are prescribed antibiotics dependent
on GPs’ views and patient expectations
(hereafter called current practice), and the
three different strategies of CRP testing for
patients presenting with RTI symptoms:
i. GP plus CRP: The patient is tested by the GP
using a point-of-care CRP test and prescribed
antibiotics accordingly.
ii. Practice nurse plus CRP: The patient is
tested by the primary care nurse using a
point-of-care CRP test and the results passed
onto the GP who prescribes antibiotics
accordingly. This strategy has been
included as a comparator since it is a
potential patient pathway considered by
GP practices who feel that it might be more
reasonable to delegate this responsibility to
the practice nurse given the time
implications of the CRP test.
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The strategy is the same as (i) GP plus CRP,
except that the GP also receives training on
communicating with patients about RTI
and antibiotics.
It is assumed that, for all three strategies with
CRP, the GP receives training on how to use
CRP as an aid to diagnosis and how to use the
CRP test. Additionally, in strategy (ii) the
practice nurse also receives training on CRP.
Model Structure
The economic evaluation consists of a decision
tree (Fig. 1) and Markov model (Fig. 2) and was
developed in Excel 2010 (Microsoft
Corporation, Redmond, WA, USA). The
structure for the decision tree is based on a
similar model developed by NICE [1]. A Markov
model was chosen for the movement between
health states as it is the most appropriate way to
calculate movements between health states
when many movements are required.
For all patients the decision tree progresses as
follows:
• current practice or one of the three CRP
arms;
• antibiotic prescription;
• if prescribed antibiotics, the risk of
antibiotic-related adverse events including
death;
• complications such as otitis media, quinsy,
or sinusitis;
• prescription of antibiotics within 28 days of
index consultation;
• complications and adverse events from
antibiotic prescriptions within 28 days of
index consultation.
At baseline, cohorts of 100 hypothetical
patients with RTI (with assumed characteristics
of adult patients that attend primary care with
RTI symptoms, i.e., 50 years old, 62% female
[9]) enter each arm of the four strategies and
receive either one of the three CRP test
strategies or current practice (no CRP test).
They then enter the decision tree (Fig. 1). The
probability that a patient is then prescribed
antibiotics is dependent on the CRP test or
current practice arm of the model they are in.
The probabilities are taken from trial data, but it
is likely that prescribing in the CRP test arms is
inﬂuenced by the results of the CRP test.
It is assumed that patients who are
prescribed antibiotics then go on to take them.
Antibiotics carry with them a risk of adverse
reactions including anaphylactic reaction to
penicillin, which carries a risk of death. Not
prescribing antibiotics carries the risk of
complications including sinusitis, otitis media
and quinsy. Antibiotic prescription carries a risk
of similar complications, but the risk is lower
[1].
The probability that patients have been
prescribed antibiotics within 28 days of
baseline (the index consultation) has been
included in the model along with the costs
and complications associated with antibiotic
prescription for patients prescribed antibiotics.
The Markov model has only two health
states: healthy and RTI. The probability of
death is only contained in the decision tree
and occurs only for patients who have an
adverse event following antibiotic prescription.
Of the two health states in the Markov model,
RTI is the only state that contains costs, since it
requires a response from the health system.
Patients that enter the RTI health state are only
those that attend primary care as a result of RTI
symptoms. The decision tree in Fig. 1 is also
used in the RTI health state to calculate the
probability of antibiotic prescription, antibiotic-
related adverse events including death,
complications associated with prescribing or
delaying antibiotics, and the probability that
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28 days of the index consultation for this
episode of RTI. The probability of being
prescribed antibiotics for an RTI after the ﬁrst
cycle in the model (ﬁrst 28 days) is based on the
resultsofthe3-yearstudybyCalsetal.[9]toreﬂect
theobservedchangeinGPbehaviorfollowingthe
index consultation and 28 days follow-up. The
two states have health state-speciﬁc outcomes,
expressed as utility scores used to calculate
quality-adjusted life years (QALYs).
Fig. 1 Decision tree for current practice and the three CRP test strategies. Decision-making criteria used to evaluate the
cost-effectiveness of CRP testing and current practice. CRP C-reactive protein
Fig. 2 Markov model for current practice and the three
C-reactive protein test strategies. The Markov model
depicts two states: healthy and respiratory tract infection
72 Adv Ther (2015) 32:69–85As stated above, the cycle length is 28 days
and the total time horizon is 3 years (40 cycles).
Three years has been chosen for the duration of
the model to reﬂect the results from the
recently published paper by Cals et al. [9].
There is no data available on GP antibiotic
prescribing and RTI infections following the
implementation of CRP for a time horizon
greater than 3 years.
Probabilities: Decision Tree
The probabilities used to populate the decision
tree are listed in Table 1 [1, 5–7, 9–11]. For the
current practice and GP plus CRP arms of the
model, the probability of patients presenting
with RTI being prescribed antibiotics at the
index consultation (baseline) was taken from a
systematic review [5]. The results of Little et al.
[7] have been added to these, since they were
published too late to be included in the
systematic review. The probability of antibiotic
prescription for practice nurse plus CRP was
derived from Cals et al. [10] as that is the point-
of-care CRP test protocol used in this study.
Antibiotic prescription at the index consultation
for the GP plus CRP and communication
training strategy was taken from Cals et al. [10]
and Little et al. [7] using the numbers reported
in the paper to calculate the percentage of
patients prescribed antibiotics.
In the decision tree, patients prescribed
antibiotics have a small percentage (0.05%)
chance of an adverse event, anaphylactic shock
[11]. Patients that have this adverse event have a
10% chance of death [1]. All patients have a
percentage chance of complications including
sinusitis, otitis media, or quinsy, although the
chance of complications is dependent on being
prescribed antibiotics at the initial consultation.
All patients also have a probability of being
prescribed antibiotics within 28 days of the
index consultation, dependent on the arm of
the model (current practice or one of the CRP
arms). The probability of being prescribed
antibiotics within 28 days of the index
consultation has been taken from the same
studies as baseline (the index consultation)
antibiotic prescription, except that no 28-day
values were available for Little et al. [7]. Patients
prescribed antibiotics within 28 days of the
initial consultation also have a percentage
chance of antibiotic-related adverse events and
complications with the same values as being
prescribed antibiotics at baseline.
The same decision tree is also used for
patients with incidents of RTI in the
subsequent cycles of the Markov model
following the ﬁrst 28 days. The only difference
between the ﬁrst decision tree and decision
trees for subsequent incidents of RTI is the
probability that patients are prescribed
antibiotics when they ﬁrst attend the GP for
this incident of the RTI. The probability that
patients are prescribed antibiotics is dependent
on the arm of the model and has been taken
from 3-year follow-up data in Cals et al. [9]
described above. This study does not include a
practice nurse plus CRP group and so these
values have been assumed to be the same as GP
plus CRP.
Probabilities: Markov Model
The transition probabilities used to populate the
Markov model are shown in Table 2 [9]. The
model replicates RTI rates from Cals et al. [9]
over 28-day cycle lengths. The RTI rates are
input as the number per person per year and
then converted into 28-day probabilities in
the model using the formula probability =
1 - exp(rate 9 time period) [12]. At baseline all
100 patients start in the RTI state, and in each
cycle all patients that have not died have 28-day
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applied. The health states of patients in
preceding cycles are independent of and do
not impact on the probability of patients being
healthy or having an RTI in subsequent cycles.
As described above, the model assumes that
the only way that a patient can die is following
an antibiotic-related adverse event. This is
captured in the decision tree only and hence
no absorbing state of death has been included
in the Markov model.
Measuring Costs
The Aﬁnion
TM Analyzer (Alere Ltd, Stockport,
UK) device [13] is used as the model for the
analysis in this study because it is widely used
across Europe for CRP testing and also used in
England for health assessments including
glycated hemoglobin (HbA1c) POCT. The costs
included in this model cover the incremental
costs of the CRP test and the costs associated
with managing an RTI in primary care in the
Table 1 Probabilities: decision tree
Value in model (%) Alpha Beta Distribution
in PSA
References
Antibiotics prescribed at index consultation
Current practice 59 5,455 3,742 Beta Huang [5], Little [7]
GP plus CRP 39 1,977 3,095 Beta Huang [5], Little [7]
Practice nurse plus CRP 41 23 33 Beta Cals [10]
GP plus CRP and communication training 35 897 1,636 Beta Cals [6], Little [7]
Antibiotics prescription within 28 days of index
Current practice 38 349 571 Beta Huang [5]
GP plus CRP 32 322 680 Beta Huang [5]
Practice nurse plus CRP 46 26 30 Beta Cals [10]
GP plus CRP and communication training 38% 76 125 Beta Cals [6]
Antibiotics prescribed for subsequent incidents of RTIs after 28 days
Current practice 36 63 113 Beta Cals [9]
GP plus CRP 31 62 141 Beta Cals [9]
Practice nurse plus CRP 31 62 141 Beta Cals [9]
GP plus CRP and communication training 26 47 131 Beta Cals [9]
Adverse events Value in model (%) Upper (%) Lower (%) Distribution in PSA References
Anaphylactic reaction to penicillin 0.05 0.1 0.0025 Beta BNF [11]
Death due to anaphylactic shock 10 20 5 Beta NICE [1]
Complications with antibiotics 1.2 1.5 0.9 Beta NICE [1]
Complications no antibiotics 4.7 5.9 3.6 Beta NICE [1]
BNF British National Formulary, CRP C-reactive protein, GP general practitioner, NICE National Institute for Health and
Care Excellence, PSA probabilistic sensitivity analysis, RTIs respiratory tract infections
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appointments for other conditions not related
to an RTI are not included, since these are
assumed to be common to all study arms and
will not affect the incremental cost.
The cost of CRP includes the cost of one GP
consultation and the cost per test of the CRP
test material, machine depreciation and GP
training for CRP. Values used in the model are
shown in Table 3 [13]. In the GP plus CRP
arm, the cost of a CRP test includes the cost
per minute of GP time multiplied by the
duration in minutes that it takes the GP to
do a CRP test. This assumes that there is an
opportunity cost associated with conducting a
CRP test, in that the time a GP spends doing
the CRP test is time that could be spent on
other patient-related activities that could
confer a different beneﬁt. In the practice
nurse plus CRP arm, the cost of CRP includes
the cost per minute of a primary care nurse
multiplied by the duration of a CRP test. The
same assumptions relating to opportunity cost
apply. The GP plus CRP and communication
training arm includes the cost in minutes of
GP time multiplied by the duration of the test
plus the cost of the communication training.
The cost of communication training is a one-
off cost per patient at baseline. In the current
practice arm, the cost of a GP consultation
only is included. The values in the model can
easily be changed as further information
becomes available.
At baseline, all patients incur the cost of a GP
consultation and the cost of a CRP test and
training, dependent on the CRP arm. In
subsequent incidents of RTI, CRP is added as a
weighted cost, the probability of which was
taken from Cals et al. [9] since not all patients
receive CRP in subsequent consultations.
The cost of antibiotics is a weighted cost
calculated from Health and Social Care
Information Centre data for 2013 on the
prescription of antibiotics used in the
treatment of RTI [14]. The cost of antibiotics
per cycle is then the average cost per
prescription multiplied by the number of
patients prescribed antibiotics each cycle at
the start of the cycle and within 28 days.
It is assumed that each RTI has an associated
weighted cost to the health service per 28 days.
The cost components currently included in the
model for each RTI are assumed to be as follows
(Table 3 [13–16], Table 4 [13, 17]):
• GP practice visit (number of visits, inclusive
of the ﬁrst visit for RTI symptoms);
• out of hours GP consultation (number of
visits);
• outpatient attendance (number of
attendances);
• hospital admission (number of admissions);
• chest X-ray (number of X-rays);
Table 2 Probabilities in Markov model: RTIs per patient, per year
Variable Value in model Upper Lower Distribution
in PSA
References
Current practice 0.39 0.45 0.32 Lognormal Cals [9]
GP plus CRP 0.34 0.40 0.28 Lognormal Cals [9]
Practice nurse plus CRP 0.34 0.40 0.28 Lognormal Cals [9]
GP plus CRP and communication training 0.33 0.36 0.29 Lognormal Cals [9]
CRP C-reactive protein, GP general practitioner, PSA probabilistic sensitivity analysis, RTIs respiratory tract infections
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• other (number of sputum or spirometry
tests).
Resource use (excluding hospital admissions)
per patient per RTI incident was taken from the
Cals et al. [18] economic evaluation of
improving management of patients with acute
cough by CRP point-of-care testing and
communication training (IMPAC3T) at 28-day
follow-up. Costs were converted to 2012/2013
prices using the hospital and community health
services index [15]. The NICE draft guidance on
pneumonia [17] found a signiﬁcant difference
in hospital admissions for CRP versus usual
care. Hospital admissions were not included in
the Cals et al. [18] analysis, but have been
included in the model in light of this ﬁnding.
There was no evidence for resource use for the
practice nurse plus CRP arm; therefore, the
same values have been used as for the GP plus
Table 3 Costs
Value in
model
Upper Lower Distribution in
PSA
References
Cost per CRP test only
Test material (reagent) £4.19 Alere [13]
Depreciation of machine £1.34 Alere [13]
Cost of GP training £0.40 Alere [13]
Duration of test: GP (min) 3 3.75 2.25 Gamma Alere [13]
Cost per minute: GP £3.80 PSSRU [15]
Duration of test: nurse (min) 5 6.25 3.75 Gamma Alere [13]
Cost per minute: nurse £0.87 PSSRU [15]
Cost per antibiotic prescription £3.11 £3.88 £2.33 Gamma Health and Social Care
Information Centre [14]
One-off cost per patient of
communication training
£5.52 Alere [13]
Unit costs
GP consultation £45.00 £56.00 £34.00 Gamma PSSRU [15]
GP out of hours £114.00 £143.00 £85.00 Gamma PSSRU [15]
Hospital outpatients £135.00 £158.00 £91.00 Gamma PSSRU [15]
Hospital admission £697.00 £846.00 £479.00 Gamma PSSRU [15]
Chest X-ray £122.00 £137.00 £74.00 Gamma NHS Reference Costs [16]
Blood £4.00 £5.00 £1.00 Gamma NHS Reference Costs [16]
Other (sputum, spirometry) £51.00 £75.00 £45.00 Gamma NHS Reference Costs [16]
CRP C-reactive protein, GP general practitioner, NHS National Health Service, PSA probabilistic sensitivity analysis,
PSSRU Personal Social Services Research Unit
76 Adv Ther (2015) 32:69–85CRP arm. Unit cost data were taken from
standard published sources and published
reports [15, 16].
Measuring Outcomes
The main outcome measure is QALYs; the
number of antibiotics prescribed and the
number of RTIs over 3 years were also
calculated.
For the measurement of QALYs, each state
in the Markov model is assigned a utility score
and the total QALYs attributable to treatment
depend on the number of patients in each
state over the time horizon of the model. The
QALYs for RTI health states are dependent on
the arm of the model. Patients that experience
an adverse event or complication have a
utility decrement for that cycle. The utility
scores associated with each state currently
used in the model are listed in Table 5 [1, 8,
18, 19]. The following assumptions are made
regarding the measurement of QALYs in the
model:
• the utility score associated with day-to-day
health is that of the general population;
• the utility score associated with RTI
symptoms is the same for all four arms of
the model;
• the utility decrement associated with adverse
events and complications is the same for all
four arms of the model;
• deaths from antibiotic-related adverse events
are assumed to occur on the ﬁrst day of each
cycle; therefore the QALYs associated with
each cycle in these states is zero;
• the duration of an RTI is determined by the
arm of the model.
When patients are in the RTI state, it is
assumed that they are healthy for all days that
they do not have an RTI. The QALY for the RTI
health state is hence calculated as 28 days,
minus the duration of an RTI, times the daily
utility score for being healthy plus the duration
of an RTI multiplied by the daily utility score for
an RTI.
Measuring Cost-Effectiveness
Cost-effectiveness is measured as the net
monetary beneﬁt (NMB) of each arm in the
model to allow for ranking of the four different
Table 4 Average resource use per patient
Variable GP plus CRP or
nurse plus CRP
GP plus CRP and
communication training
Current
practice
CRP test [13] 0.04 0.04 N/A
GP consultation [13] 1.4 1.27 1.37
GP out of hours [13] 0.01 0.02 0.08
Hospital outpatients [13] 0.02 0.02 0
Hospital admission [17] 0.009 0.009 0.003
Chest x-ray [13] 0.05 0.09 0.07
Blood [13] 0.01 0.05 0.0
Other (sputum, spirometry) [13] 0.02 0.02 0.02
CRP C-reactive protein, GP general practitioner
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considered the most favorable option. NMB is
calculated as the total QALYs, multiplied by the
willingness to pay (WTP) for a QALY, minus the
total cost.
The time horizon of the model is 3 years. An
annual discount rate of 3.5% for future costs
and beneﬁts is used, applied as a discount rate
per cycle of 0.26%. All costs are calculated based
on prices in 2012/2013, in UK pounds. The
analytical perspective is the health service; any
cost implications to social services, the
individual, the family or employers are
excluded.
Values for the total discounted cost and
QALYs for each option are provided in Table 5
[1, 8, 18, 19].
Sensitivity Analysis
Uncertainty in costs and outcomes is
investigated in the model with a probabilistic
sensitivity analysis (PSA) [20] of 5,000
replications. A scatter plot of the cost-
effectiveness plane showing incremental costs
per 100 patients and the QALY gains per 100
patients of the three CRP test strategies
compared with current practice, which is
assumed to be at the origin on the cost-
effectiveness plane, is plotted for each
replication. The probability that each of the
four strategies has the highest NMB at various
thresholds of WTP for a QALY—the cost-
effectiveness acceptability curve (CEAC) [21]—
is also plotted. Head-to-head comparisons of
standard care compared to any options that are
not dominated or eliminated by extended
dominance are also reported.
The variables allowed to vary in the PSA,
probability distributions and parameter values
in the model are shown in Tables 1, 2, 3 and 4
and are chosen in line with the methodology
set out in Briggs et al. [12]. One-way sensitivity
analyses of key parameters in the model were
also conducted.
The analysis was repeated for a 9-year time
horizon (120 cycles of 28 days per cycle) to
evaluate the impact on the results.
Table 5 QALYs
Value in
model
Standard
error
Distribution in
PSA
References
Utility scores
Utility score: health 0.86 0.003949 Beta Kind [19]
Utility score: RTI 0.674 0.010138 Beta Oppong [8]
Utility decrement: adverse event -0.2 NICE [1]
Duration of RTI (days)
Current practice 9.7 0.56598 Gamma Cals [18]
GP plus CRP 9.1 0.591147 Gamma Cals [18]
Practice nurse plus CRP 9.1 0.591147 Gamma Cals [18]
GP plus CRP and communication training 11 0.637905 Gamma Cals [18]
CRP C-reactive protein, GP general practitioner, NICE National Institute for Health and Care Excellence, PSA
probabilistic sensitivity analysis, RTI respiratory tract infection
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RESULTS
Deterministic Analysis
The results of the deterministic analysis are
reported in Table 6. For the deterministic
Table 6 Results for 3 years per 100 patients
Statistic Current practice GP plus CRP Practice nurse plus CRP GP plus CRP and
communication
Total cost (discounted) £18,081 £18,039 £17,401 £18,431
QALYs (discounted) 255.630 255.764 255.761 255.588
Antibiotics prescribed (courses) 184 136 167 137
Infections 217.89 202.97 202.97 199.98
Per-patient NMB
(£20,000 per QALY)
£50,945 £50,972 £50,978 £50,933
CRP C-reactive protein, GP general practitioner, NMB net monetary beneﬁt, QALY quality-adjusted life year
Fig. 3 Cost-effectiveness plane: current practice compared
to GP plus CRP, practice nurse plus CRP, and GP plus
CRP and communication training. Three-year time
horizon, 100 patients and discounted costs and QALYs.
1,000 iterations. CRP C-reactive protein, GP general
practitioner, QALYs quality-adjusted life years
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CRP test both dominate (cost less and result in
more QALYs) compared to current practice
over 3 years. The two strategies result in 0.13
additional QALYs per 100 patients (discounted)
and cost £42 less per 100 patients (discounted)
for GP plus CRP and £680 less per 100 patients
(discounted) for practice nurse plus CRP. GP
plus CRP test and communication training is
dominated by current practice as it costs more
and results in fewer QALYs. All three CRP arms
result in fewer antibiotic prescriptions and
infections over 3 years than current practice.
Probabilistic Sensitivity Analysis
The results for each of the simulations of
the model compared to current practice are
presented on a cost-effectiveness plane in Fig. 3.
The GP plus CRP test strategy is dominant (costs
less and results in more QALYs) compared to
current practice in 50% of simulations; in 65%
of simulations the practice nurse plus CRP test
strategy is dominant and in 19% the GP plus
CRP and communication training strategy is
dominant.
A CEAC comparing the proportion of
iterations of the PSA where each option has
the highest NMB for a range of values of WTP
for a QALY is presented in Fig. 4. The practice
nurse plus CRP strategy has the highest
proportion of iterations with the highest NMB
across all values of WTP for a QALY, with values
between 49% and 53%.
Cost-effectiveness acceptability curves
comparing current practice against GP plus
CRP and practice nurse plus CRP are reported
in Figs. 5 and 6, respectively. At a WTP of
Fig. 4 Cost-effectiveness acceptability curve: current
practice compared to GP plus CRP, practice nurse plus
CRP, and GP plus CRP and communication training.
Three-year time horizon, 100 patients and discounted
costs and QALYs. 5,000 iterations. CRP C-reactive
protein, GP general practitioner, NMB net monetary
beneﬁt, QALYs quality-adjusted life years
80 Adv Ther (2015) 32:69–85£20,000 per QALY, GP plus CRP has a higher
NMB than current practice for 77% of
iterations and practice nurse plus CRP has a
higher NMB than current practice for 82% of
iterations. The analysis for GP plus CRP and
communication training was not presented
given that it is dominated by the other three
options.
The results of the one-way sensitivity
analysis are presented in Table 7. Changing
most of the key parameters in the model has
little impact on the conclusions, except for
standardizing the length of RTI. If the length of
RTI is standardized across all arms GP plus CRP
and communication has a higher NMB than GP
plus CRP and current practice, but not practice
nurse plus CRP.
The results remain the same for the 9-year
time horizon (see Fig. 7).
DISCUSSION
Summary of Results
Over a 3-year time horizon, two of the CRP test
strategies, GP plus CRP test and practice nurse
plus CRP test, have a higher NMB than current
practice, although this difference is minimal.
The additional cost per patient of the CRP test is
outweighed by the associated cost savings and
QALY increment associated with a reduction in
infections in the long term. This result is mostly
driven by the results of Cals et al. [9] which
found that a point-of-care CRP test resulted in
reduced risk of RTI per person per year
compared to current practice, although the
change was not signiﬁcant.
Although communication training in
addition to the GP CRP test also results in
Fig. 5 Cost-effectiveness acceptability curve: current
practice compared to GP plus CRP. Three-year time
horizon, 100 patients and discounted costs and QALYs.
5,000 iterations. CRP C-reactive protein, GP general
practitioner, NMB net monetary beneﬁt, QALYs quality-
adjusted life years
Adv Ther (2015) 32:69–85 81Fig. 6 Cost-effectiveness acceptability curve: current
practice compared to practice nurse plus CRP. Three-year
time horizon, 100 patients and discounted costs and
QALYs. 5,000 iterations. CRP C-reactive protein, NMB
net monetary beneﬁt, QALYs quality-adjusted life years
Table 7 One-way sensitivity analyses of net monetary beneﬁt (NMB) per patient over 3 years at £20,000 per QALY
Variable modiﬁed Current
practice
GP plus
CRP
Practice nurse
plus CRP
GP plus CRP and
communication
CRP test costs 50% more £50,945 £50,970 £50,975 £50,936
CRP test costs 100% more £50,945 £50,967 £50,972 £50,933
CRP test takes twice as long £50,945 £50,961 £50,974 £50,927
Antibiotics cost twice as much £50,940 £50,968 £50,973 £50,935
Duration of RTI is 7 days £51,003 £51,015 £51,020 £51,018
Duration of RTI is 11 days £50,917 £50,934 £50,940 £50,939
Twice the risk of anaphylaxis £50,942 £50,970 £50,975 £50,936
Twice the risk of complications with
antibiotics
£50,944 £50,972 £50,978 £50,938
Twice the risk of complications with no
antibiotics
£50,943 £50,970 £50,976 £50,937
Utility score of 1 if healthy £59,145 £59,192 £59,198 £59,132
82 Adv Ther (2015) 32:69–85reduced risk of infection and antibiotic
prescribing, this is not sufﬁcient to outweigh
the additional cost of training. Two studies, Cals
et al. [10] and Little et al. [7], also found that the
duration of RTI symptoms is signiﬁcantly longer
for patients in communication training arms of
trials, although only the results from Cals et al.
[10] have been included in this model. The
extended duration of symptoms is the likely
explanation for why the GP plus CRP test plus
communication training arm of the model also
resulted in fewer QALYs than current practice,
as shown by the results of the one-way
sensitivity analysis. This also suggests that if
CRP testing were implemented in NHS England,
the most cost-effective options would also be
the least resource intensive to implement:
practice nurses and/or GPs would only need
training in using CRP tests, with questionable
additional beneﬁt being gained from more
intensive communication training.
Strengths and Weaknesses
This is the ﬁrst study to report the cost-
effectiveness of different strategies of CRP tests
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Fig. 7 Cost-effectiveness acceptability curve: current
practice compared to GP plus CRP, practice nurse plus
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Table 7 continued
Variable modiﬁed Current
practice
GP plus
CRP
Practice nurse
plus CRP
GP plus CRP and
communication
Utility score 0.1 higher for the duration of an RTI £51,058 £51,071 £51,077 £51,056
Utility score 0.1 lower for the duration of an RTI £50,833 £50,874 £50,880 £50,821
CRP C-reactive protein, GP general practitioner, RTI respiratory tract infection
Adv Ther (2015) 32:69–85 83for RTI in primary care over a time horizon
greater than 28 days; the model takes multiple
factors into consideration and can be amended
as further data become available.
However, the model has some limitations.
Firstly, there are limited data on long-term
antibiotic prescribing, health-care resource use
and incidence of RTI for the point-of-care CRP
strategy where the practice nurse conducts the
CRP test followed by a consultation with the GP.
Instead,theassumptionwasmadethattheresults
are the same as the GP conducting the CRP test
and prescribing antibiotics for the missing
variables. Given that the cost-effectiveness of the
different strategies is strongly driven by these
values, it reduces the strength of conﬁdence in
these results and the ability to validate the model
using another data set.
Secondly, the 3-year follow-up results in Cals
et al. [9] only capture the incidence of RTI
where patients present to their GP with
symptoms. If patients are discouraged from
attending their GP because at their index
appointment for RTI symptoms they were less
likely to be prescribed antibiotics after having
received a CRP test, they may perceive there is
less value in attending the GP for subsequent
RTIs. Hence, the reduced incidence of reported
RTI may only be due to reduced primary care
attendance, and not an actual reduction in RTI
incidence. Although this is correctly reﬂected in
the cost, as less attendance means reduced cost,
there is the possibility that some of the
disutility of having an RTI might be missing
from the CRP arms of the model.
CONCLUSION
Over the 3-year period, two of the CRP test
strategies, GP plus CRP test and practice nurse
plus CRP test, are dominant over current
practice. Further work should be carried out to
determine whether any differences exist
between the nurse plus CRP test strategy and
GP plus CRP test strategy for the missing
variables in this study. The data suggest that
these strategies are associated with reduced risks
of infection and antibiotic prescribing, in
combination with increased QALYs, and
therefore could be implemented cost-
effectively in primary care as a potential
strategy to help reduce unnecessary antibiotic
prescriptions. This would contribute to the
ongoing national and international efforts to
reduce antibiotic-resistant infections.
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